Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G 1 checkpoint-defective neuroblastoma

International Journal of Cancer

Volumn 129, Issue 8, 2011, Pages 1953-1962

  Xu, Hong ^a   Cheung, Irene Y ^a   Wei, Xiao X ^a   Tran, Hoa ^a   Gao, Xiaoni ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

AZD7762; cell cycle checkpoint; Chk1; neuroblastoma; synergism

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; [3 (CARBAMOYLAMINO) 5 (3 FLUOROPHENYL) N (3 PIPERIDYL)THIOPHENE 2 CARBOXAMIDE]; ANTINEOPLASTIC AGENT; AZD 7762; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; MELPHALAN; MUTANT PROTEIN; NOCODAZOLE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN MDM2; PROTEIN P53; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG TREATMENT FAILURE; FEMALE; GENOMICS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFECT; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, NUDE; NEUROBLASTOMA; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; THIOPHENES; UREA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80051957430     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25842     Document Type: Article

References (31)

1. Harper JW, Elledge SJ,. The DNA damage response: ten years after. Mol Cell 2007; 28: 739-45. (Pubitemid 350217064)
2. Lapenna S, Giordano A,. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009; 8: 547-66.
3. Dai Y, Grant S,. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 2010; 16: 376-83.
4. Ashwell S, Janetka JW, Zabludoff S,. Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. Expert Opin Investig Drugs 2008; 17: 1331-40.
5. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, Liu D, Mouchet E, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008; 7: 2955-66.
6. Keshelava N, Seeger RC, Groshen S, Reynolds CP,. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998; 58: 5396-405. (Pubitemid 28551122)
7. Carr J, Bell E, Pearson AD, Kees UR, Beris H, Lunec J, Tweddle DA,. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res 2006; 66: 2138-45.
8. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ, Reynolds CP,. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 2001; 61: 6185-93. (Pubitemid 32768583)
9. Vogelstein B, Lane D, Levine AJ,. Surfing the p53 network. Nature 2000; 408: 307-10.
10. Cattelani S, Defferrari R, Marsilio S, Bussolari R, Candini O, Corradini F, Ferrari-Amorotti G, Guerzoni C, Pecorari L, Menin C, Bertorelle R, Altavista P, et al. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients. Clin Cancer Res 2008; 14: 3248-53.
11. Perfumo C, Parodi S, Mazzocco K, Defferrari R, Inga A, Scarra GB, Ghiorzo P, Haupt R, Tonini GP, Fronza G,. MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma. Pediatr Blood Cancer 2009; 53: 576-83.
12. Van Maerken T, Vandesompele J, Rihani A, De Paepe A, Speleman F,. Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis. Cell Death Differ 2009; 16: 1563-72.
13. ARF Pathway Abnormalities in Relapsed Neuroblastoma. Clin Cancer Res 2010; 16: 1108-18.
14. Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J,. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 2001; 61: 8-13. (Pubitemid 32095689)
15. Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS,. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 1978; 38: 3751-7. (Pubitemid 9045201)
16. Tumilowicz JJ, Nichols WW, Cholon JJ, Greene AE,. Definition of a continuous human cell line derived from neuroblastoma. Cancer Res 1970; 30: 2110-8.
17. Davidoff AM, Pence JC, Shorter NA, Iglehart JD, Marks JR,. Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene 1992; 7: 127-33.
18. Goldschneider D, Horvilleur E, Plassa LF, Guillaud-Bataille M, Million K, Wittmer-Dupret E, Danglot G, de The H, Benard J, May E, Douc-Rasy S,. Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res 2006; 34: 5603-12. (Pubitemid 44742447)
19. McKenzie PP, Guichard SM, Middlemas DS, Ashmun RA, Danks MK, Harris LC,. Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated. Clin Cancer Res 1999; 5: 4199-207. (Pubitemid 30013806)
20. Rudolph G, Schilbach-Stuckle K, Handgretinger R, Kaiser P, Hameister H,. Cytogenetic and molecular characterization of a newly established neuroblastoma cell line LS. Hum Genet 1991; 86: 562-6.
21. Brodeur GM, Sekhon GS, Goldstein MN,. Chromosomal aberations in human neuroblastomas. Cancer 1977; 40: 2256-63.
22. Wada RK, Seeger RC, Brodeur GM, Slamon DJ, Rayner SA, Tomayko M, Reynolds CP,. Characterization of human neuroblastoma cell lines that lack N-myc gene amplification. Prog Clin Biol Res 1988; 271: 57-69.
23. Tweddle DA, Pearson AD, Haber M, Norris MD, Xue C, Flemming C, Lunec J,. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett 2003; 197: 93-8. (Pubitemid 36859996)
24. Xu B, Kim ST, Lim DS, Kastan MB,. Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol Cell Biol 2002; 22: 1049-59. (Pubitemid 34094842)
25. Chou TC,. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-81.
26. Laverdiere C, Liu Q, Yasui Y, Nathan PC, Gurney JG, Stovall M, Diller LR, Cheung NK, Wolden S, Robison LL, Sklar CA,. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009; 101: 1131-40.
27. Kushner BH, Kramer K, LaQuaglia MP, Modak S, Yataghene K, Cheung NK,. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol 2004; 22: 4888-92. (Pubitemid 46638612)
28. Petermann E, Maya-Mendoza A, Zachos G, Gillespie DA, Jackson DA, Caldecott KW,. Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase. Mol Cell Biol 2006; 26: 3319-26.
29. Sampath D, Rao VA, Plunkett W,. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003; 22: 9063-74. (Pubitemid 38121707)
30. McNeely S, Conti C, Sheikh T, Patel H, Zabludoff S, Pommier Y, Schwartz G, Tse A,. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. Cell Cycle 2010; 9: 995-1004.
31. Ogawa M, Hori H, Ohta T, Onozato K, Miyahara M, Komada Y,. Sensitivity to gemcitabine and its metabolizing enzymes in neuroblastoma. Clin Cancer Res 2005; 11: 3485-93. (Pubitemid 40627903)